GRAIL announced plans to present new support for the Galleri test's ability to simultaneously screen for multiple cancers plus its accuracy for cancer signal of origin prediction.
An interview with Jeff Andrews, MD, FRCSC, of BD Life Sciences
ACP 2025: Dr Kalager shares strategies for addressing patient beliefs, presenting risk data, and promoting shared decision-making in primary care settings.
The increase in pancreatic cancer among Americans aged 15 to 34 is particularly alarming and should alert clinicians to heed relevant GI symptoms as suspicious.
The phone-based patient navigation intervention addressed barriers to CRC testing follow-up and included patient education.